6 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| C4 Therapeutics, Inc. | 4 |
| C4 Therapeutics, Inc. | 2 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19303091 | Untitled | C4 Therapeutics, Inc. | HABTE, KAHSAY | 1624 | Non-Final OA | |
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. | AULAKH, CHARANJIT | 1621 | Non-Final OA | Dec 08, 2023 |
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 Therapeutics, Inc. | ELENISTE, PIERRE PAUL | 1622 | Non-Final OA | Nov 21, 2023 |
| 18385277 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 Therapeutics, Inc. | HIRAKIS, SOPHIA P | 1623 | Final Rejection | Oct 30, 2023 |
| 17771204 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 Therapeutics, Inc. | ENGLISH, CONNOR KENNEDY | 1625 | Non-Final OA | Apr 22, 2022 |
| 17723199 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. | HIRAKIS, SOPHIA P | 1623 | Non-Final OA | Apr 18, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial